The "Preserving Patient Access to Home Infusion Act" seeks to amend Medicare's Title XVIII to improve patient access to home infusion therapy. It expands the definition of home infusion therapy services to explicitly include pharmacy services , such as assessments, drug preparation, compounding, and coordination of care. Furthermore, the bill permits nurse practitioners and physician assistants , in addition to physicians, to establish and periodically review a patient's home infusion plan of care, effective January 1, 2026. The legislation also introduces several modifications to the payment structure for home infusion therapy. It clarifies that payment for an infusion drug administration calendar day applies to each day a drug is administered, irrespective of whether a qualified supplier is physically present. A transitional rule for 2026 through 2030 ensures the single payment amount reflects five hours of infusion per therapy per day. When a qualified home infusion therapy supplier is not physically present in the individual's home, the payment amount for services on that day will be 50 percent of the standard rate. To further broaden access, the bill modifies the definition of a home infusion drug to include "specified non-pump drugs or biologicals," such as intravenously administered antibacterial, antifungal, or antiviral drugs not requiring a durable medical equipment pump. It clarifies that associated nursing and pharmacy services for these non-pump drugs will be paid for, even if the drug itself is not directly payable under Medicare Part B. Finally, a special payment rule prohibits separate Medicare payment for certain supplies like tubing, catheters, and dressings when furnished on the same day as and in conjunction with home infusion therapy.